Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

This drugmaker is no stranger to controversy.

2 Red Flags for Biogen's Future

Scientists are criticizing the publication of results from late-stage trials of Aduhelm in a small and relatively unknown journal.

Biogen's Aduhelm Credibility Problem Deepens. Investors Are Paying the Price.

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer's Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-studies.

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease

Philadelphia, Pennsylvania--(Newsfile Corp. - March 16, 2022) - Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) between June 7, 2021 and January 11, 2022 (the "Class Period"). If you purchased Biogen securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or...

Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022

Shares of Biogen Inc. BIIB, +1.85% gained 4.3% in premarket trading on Wednesday after the company announced new data for its Alzheimer's disease drug demonstrating reductions in amyloid beta plaques for 132 weeks and plasma p-tau181 for 128 weeks. The company also said in a news release that the clinical-trial data show that patients with lower plasma p-tau181 levels had less clinical decline.

Biogen's stock gains after sharing longer term data for its Alzheimer's disease

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM® (aducanumab-avwa) injection 100 mg/mL for intravenous use, patients in the long-term extension phase of the Phase 3 trials continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid beta plaques and plasma p-tau181. The data also show that in both Phase 3 trials, at 78 weeks, patients with reduced levels of plasma p-tau181 had less clinical decline than those whose plasma p-tau181 levels were not reduced.

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer's Disease in Patients Treated for More Than Two Years

CAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when annual sales exceed $1 billion. Effective immediately, Biogen's existing final decision-making rights on ADUHELM have converted to sole decision making and commercialization rights worldwide. Overall, economic arrangements for both companies in 2022 are expected to remain materially unchanged with Eisai's share of expenses capped at an agreed amount for the costs related to development, commercialization, and manufacturing of ADUHELM for the period from January 1, 2022 to December 31, 2022. Once the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM's economics beyond these royalties.

Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments

Advertising campaign aimed at expanding Medicare payment for Aduhelm

Advocacy Groups Spending Millions to Influence Decision of Biogen Alzheimer's Treatment

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates will be presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer's disease research, as well as data for ADUHELM® (aducanumab-avwa) injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022), taking place March 15-20 in Barcelona, Spain and virtually. These data include analyses of treatment effect on biomarkers of Alzheimer's disease in the long-term extension studies, with over two years of Phase 3 data.

Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Biogen stock is near a multi-year low. The pipeline of potential new drugs is deep.

Biogen: Beyond The Doom And Gloom

PHILADELPHIA, March 3, 2022 /PRNewswire/ --  Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) between June 7, 2021 and January 11, 2022 (the "Class Period"). If you purchased Biogen securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Michael Dell'Angelo at mdellangelo@bm.net or (215) 875-3080 or visit: https://investigations.bergermontague.com/biogen-inc/  Whistleblowers: Anyone with non-public information regarding Biogen is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program.

Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022

TOKYO and CAMBRIDGE, Mass., March 3, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401). The lecanemab Clarity AD Phase 3 clinical study for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) is ongoing.

EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB

Shares of Biogen Inc. BIIB, +1.08% were up 1.0% in trading on Thursday after the company confirmed to media outlets that it is laying off some U.S. employees as part of an effort to secure $500 million in annual cost savings. Stat first reported the layoffs, saying the company plans to cut 1,000 jobs, citing anonymous sources.

Biogen to lay off some U.S. employees

Will Aduhelm's controversial approval signal a new normal for clinical trials?

What Investors Can Learn From Biogen's Drug Approval That No One Wants

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Biogen Inc.. Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)

NEW YORK, Feb. 22, 2022 /PRNewswire/ -- Attention Biogen Inc. ("Biogen") (NASDAQ: BIIB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 7, 2021 and January 11, 2022. If you suffered a loss on your investment in Biogen, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022

Could Advocacy Groups' Campaign for Aduhelm Benefit Biogen?

San Francisco, California--(Newsfile Corp. - February 18, 2022) - Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: June 7, 2021 - Jan. 11, 2022Lead Plaintiff Deadline: April 8, 2022Visit: www.hbsslaw.com/investor-fraud/BIIBContact An Attorney Now: BIIB@hbsslaw.com844-916-0895Biogen Inc. (BIIB) Securities Class Action: The lawsuit focuses on Biogen's and senior ma

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Case Pending

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/biogen-inc-loss-submission-form-2/?id=23818&from=4 The lawsuit seeks to recover losses for shareholders who purchased Biogen between June 7, 2021 and January 11, 2022.

BIIB SHAREHOLDER ALERT: Jakubowitz Law Reminds Biogen Shareholders of a Lead Plaintiff Deadline of April 8, 2022

San Francisco, California--(Newsfile Corp. - February 16, 2022) -  Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: June 7, 2021 - Jan. 11, 2022Lead Plaintiff Deadline: April 8, 2022Visit: www.hbsslaw.com/investor-fraud/BIIB Contact An Attorney Now: BIIB@hbsslaw.com 844-916-0895Biogen Inc. (BIIB) Securities Class Action: The...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed

SAGE Therapeutics

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study. The drug, zuranolone, also met the study's secondary goal of showing an improvement in symptoms when administered with a standard of care antidepressant, compared to a combination of placebo and antidepressants over two weeks.

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

All of them are directly related to Aduhelm.

3 Red Flags for Biogen's Future

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives, demonstrating a rapid and statistically significant reduction in depressive symptoms at Day 3 and over the 2-week treatment period, achieving the primary and key secondary endpoints. This significance was demonstrated at the first measured time point, Day 3, with zuranolone 50 mg co-init

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alleging that the Company violated federal securities laws. Class Period: June 7, 2021 to January 11, 2022 Lead Plaintiff Deadline: April 8, 2022 No obligation or cost to you.

News for Biogen Stock (BIIB)